312 related articles for article (PubMed ID: 24882384)
1. Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution.
Raphael J; Le Teuff G; Hollebecque A; Massard C; Bahleda R; Margery J; Besse B; Soria JC; Planchard D
Lung Cancer; 2014 Aug; 85(2):251-7. PubMed ID: 24882384
[TBL] [Abstract][Full Text] [Related]
2. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
Zucali PA; Perrino M; Lorenzi E; Ceresoli GL; De Vincenzo F; Simonelli M; Gianoncelli L; De Sanctis R; Giordano L; Santoro A
Lung Cancer; 2014 Jun; 84(3):265-70. PubMed ID: 24321581
[TBL] [Abstract][Full Text] [Related]
3. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
Tsao AS; Miao J; Wistuba II; Vogelzang NJ; Heymach JV; Fossella FV; Lu C; Velasco MR; Box-Noriega B; Hueftle JG; Gadgeel S; Redman MW; Gandara DR; Kelly K
J Clin Oncol; 2019 Oct; 37(28):2537-2547. PubMed ID: 31386610
[TBL] [Abstract][Full Text] [Related]
4. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
Hassan R; Kindler HL; Jahan T; Bazhenova L; Reck M; Thomas A; Pastan I; Parno J; O'Shannessy DJ; Fatato P; Maltzman JD; Wallin BA
Clin Cancer Res; 2014 Dec; 20(23):5927-36. PubMed ID: 25231400
[TBL] [Abstract][Full Text] [Related]
5. Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma.
Klikovits T; Stockhammer P; Laszlo V; Dong Y; Hoda MA; Ghanim B; Opitz I; Frauenfelder T; Nguyen-Kim TDL; Weder W; Berger W; Grusch M; Aigner C; Klepetko W; Dome B; Renyi-Vamos F; Oehler R; Hegedus B
Sci Rep; 2017 Nov; 7(1):16456. PubMed ID: 29184132
[TBL] [Abstract][Full Text] [Related]
6. A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
Nowak AK; Brown C; Millward MJ; Creaney J; Byrne MJ; Hughes B; Kremmidiotis G; Bibby DC; Leske AF; Mitchell PLR; Pavlakis N; Boyer M; Stockler MR
Lung Cancer; 2013 Sep; 81(3):422-427. PubMed ID: 23787063
[TBL] [Abstract][Full Text] [Related]
7. Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma.
Li F; Ahmad M; Qayyum F; Straus CM; MacMahon H; Kindler H; Armato SG
Eur Radiol; 2019 Jun; 29(6):2981-2988. PubMed ID: 30617480
[TBL] [Abstract][Full Text] [Related]
8. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
Gregorc V; Gaafar RM; Favaretto A; Grossi F; Jassem J; Polychronis A; Bidoli P; Tiseo M; Shah R; Taylor P; Novello S; Muzio A; Bearz A; Greillier L; Fontana F; Salini G; Lambiase A; O'Brien M
Lancet Oncol; 2018 Jun; 19(6):799-811. PubMed ID: 29753703
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of the Efficacy of Pemetrexed Maintenance Therapy in Patients with
Malignant Pleural Mesothelioma].
Zeng X; Jiang Z; Duan J
Zhongguo Fei Ai Za Zhi; 2022 Jan; 25(1):7-13. PubMed ID: 35078279
[TBL] [Abstract][Full Text] [Related]
10. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.
Zauderer MG; Kass SL; Woo K; Sima CS; Ginsberg MS; Krug LM
Lung Cancer; 2014 Jun; 84(3):271-4. PubMed ID: 24690410
[TBL] [Abstract][Full Text] [Related]
11. Pathological complete response in malignant pleural mesothelioma patients following induction chemotherapy: Predictive factors and outcomes.
Lau B; Kumar S; Yan T; Burn J; Kennedy C; McLean J; Boyer M; McCaughan B; Kao S
Lung Cancer; 2017 Sep; 111():75-78. PubMed ID: 28838403
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
[TBL] [Abstract][Full Text] [Related]
13. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
van Zandwijk N; Pavlakis N; Kao SC; Linton A; Boyer MJ; Clarke S; Huynh Y; Chrzanowska A; Fulham MJ; Bailey DL; Cooper WA; Kritharides L; Ridley L; Pattison ST; MacDiarmid J; Brahmbhatt H; Reid G
Lancet Oncol; 2017 Oct; 18(10):1386-1396. PubMed ID: 28870611
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy Versus Supportive Care for Unresected Malignant Pleural Mesothelioma.
Verma V; Wegner RE; Brooks ED; Miccio JA; Kann BH; Finley GG; Raj MS; Grover S; Mohindra P; Simone CB
Clin Lung Cancer; 2019 Jul; 20(4):263-269. PubMed ID: 30992187
[TBL] [Abstract][Full Text] [Related]
15. Secondline chemotherapy versus best supportive care in patient with malignant pleural mesothelioma: a retrospective study.
Mutlu H; Buyukcelik A; Karaca H; Aksahin A; Berk V; Aslan T; Erden A; Akca Z; Ozkan M
Asian Pac J Cancer Prev; 2013; 14(6):3887-9. PubMed ID: 23886202
[TBL] [Abstract][Full Text] [Related]
16. Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?".
Di Noia V; Vita E; Ferrara M; Strippoli A; Basso M; Schinzari G; Cassano A; Bria E; Barone C; D'Argento E
Curr Treat Options Oncol; 2019 Feb; 20(3):23. PubMed ID: 30790063
[TBL] [Abstract][Full Text] [Related]
17. A review of bevacizumab in the treatment of malignant pleural mesothelioma.
Brosseau S; Assoun S; Naltet C; Steinmetz C; Gounant V; Zalcman G
Future Oncol; 2017 Dec; 13(28):2537-2546. PubMed ID: 29086616
[TBL] [Abstract][Full Text] [Related]
18. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
Fennell DA; Baas P; Taylor P; Nowak AK; Gilligan D; Nakano T; Pachter JA; Weaver DT; Scherpereel A; Pavlakis N; van Meerbeeck JP; Cedrés S; Nolan L; Kindler H; Aerts JGJV
J Clin Oncol; 2019 Apr; 37(10):790-798. PubMed ID: 30785827
[TBL] [Abstract][Full Text] [Related]
19. Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma.
Raphael J; Massard C; Gong IY; Farace F; Margery J; Billiot F; Hollebecque A; Besse B; Soria JC; Planchard D
Cancer Biomark; 2015; 15(2):151-6. PubMed ID: 25519011
[TBL] [Abstract][Full Text] [Related]
20. ERCC1 as a biological marker guiding management in malignant pleural mesothelioma.
Cihan YB; Ozturk A; Arslan A; Deniz K; Baran M; Karaca H
Asian Pac J Cancer Prev; 2014; 15(10):4117-23. PubMed ID: 24935356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]